Letter: the treatment of coronary artery disease in cirrhotics needs more thinking-author's reply

L A Feagins^{1

2}

Affiliations

¹ Divisions of Gastroenterology and Hepatology, VA North Texas Healthcare System, Dallas, TX, USA.
² Division of Digestive and Liver Disease, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Comment

L A Feagins. Aliment Pharmacol Ther. 2017 Sep.

. 2017 Sep;46(6):639.

doi: 10.1111/apt.14232.

L A Feagins^{1

2}

¹ Divisions of Gastroenterology and Hepatology, VA North Texas Healthcare System, Dallas, TX, USA.
² Division of Digestive and Liver Disease, University of Texas Southwestern Medical Center, Dallas, TX, USA.

No abstract available

Comment on

Patients with cirrhosis who have coronary artery disease treated with cardiac stents have high rates of gastrointestinal bleeding, but no increased mortality.
Krill T, Brown G, Weideman RA, Cipher DJ, Spechler SJ, Brilakis E, Feagins LA. Krill T, et al. Aliment Pharmacol Ther. 2017 Jul;46(2):183-192. doi: 10.1111/apt.14121. Epub 2017 May 9. Aliment Pharmacol Ther. 2017. PMID: 28488370
Letter: the treatment of coronary artery disease in cirrhotics needs more thinking.
Zhao J, Tian H, Liang C. Zhao J, et al. Aliment Pharmacol Ther. 2017 Sep;46(6):638-639. doi: 10.1111/apt.14225. Aliment Pharmacol Ther. 2017. PMID: 28805332 No abstract available.